{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:24:01Z","timestamp":1780053841706,"version":"3.54.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Polypharmacy is a rising morbidity amongst patients with chronic heart failure (CHF), with reported prevalence ranging from 70% to 85%. While polypharmacy is essential for managing comorbid conditions, its exact impact on heart failure outcomes is still emerging. This study aims to examine the effects of different polypharmacy phenogroups on mortality and intensive care unit (ICU) admissions across various heart failure phenotypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective cross-sectional study involving 4,902 patients with chronic heart failure treated at Hamad Medical Corporation, Doha, Qatar, between January 2018 and January 2022. Patients were classified into three polypharmacy groups: no polypharmacy (0\u20134 medications), major polypharmacy (five to eight medications), and excessive polypharmacy (\u22659 medications). Heart failure phenotypes were categorized based on ejection fraction (EF): reduced EF (HFrEF, &amp;lt;40%), mildly reduced EF (HFmrEF, 40%\u201349%), and preserved EF (HFpEF, \u226550%). The primary outcome was all-cause mortality, with secondary outcomes including intensive care unit (ICU) admissions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A cohort of 4,902 patients with chronic heart failure, with a mean age of 61.47 years (SD 15.99), was analyzed. Among them, 51.7% had heart failure with reduced ejection fraction (HFrEF), 16.2% had mildly reduced ejection fraction (HFmrEF), and 32% had preserved ejection fraction (HFpEF). Major polypharmacy due to guideline-directed medical therapy (GDMT), was associated with a significant improvement in survival. In patients with HFpEF, the hazard ratio (HR) for all-cause mortality was 0.62 (95% CI: 0.52-0.75, p &amp;lt; 0.001), while for HFmrEF, it was 0.70 (95% CI: 0.59-0.85, p = 0.001). Conversely, excessive polypharmacy involving non-heart failure medications, was linked to increased ICU admissions (odds ratio [OR]: 1.34, 95% CI: 1.10-1.62, p = 0.02). Cox proportional hazards models demonstrated that excessive polypharmacy was associated with a hazard ratio of 0.11 (95% CI: 0.05-0.23, p &amp;lt; 0.001) for all-cause mortality when the medications were primarily heart failure-specific.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with chronic Heart failure, guideline directed polypharmacy was associated with improved survival, particularly in HFpEF and HFmrEF phenotypes. However, non-heart failure-related polypharmacy is associated with worse outcomes including ICU admissions, necessitating need for targeted interventions for this group of patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1526112","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:15:45Z","timestamp":1746504945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of polypharmacy phenogroups on different heart failure phenotypes in patients with chronic heart failure: a retrospective examination of real-world cohort"],"prefix":"10.3389","volume":"16","author":[{"given":"Aseel","family":"Sukik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Tarek","family":"Aboughalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Haseeb","family":"Said Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Al Radaideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Mohamed","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joud Said","family":"Abuodeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyelola A.","family":"Adegboye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdelNaser","family":"Elzouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ibn-Mas\u2018ud","family":"Danjuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/nejmoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10741-021-10135-4","article-title":"Polypharmacy definition and prevalence in heart failure: a systematic review","volume":"27","author":"Beezer","year":"2022","journal-title":"Heart Fail Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e003529","DOI":"10.1161\/circheartfailure.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ. Heart Fail."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet Lond Engl."},{"key":"B5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson comorbidity index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother. Psychosom."},{"key":"B6","doi-asserted-by":"publisher","first-page":"102194","DOI":"10.1016\/j.cpcardiol.2023.102194","article-title":"In patients with chronic heart failure, which polypharmacy pheno-groups are associated with adverse health outcomes? (Polypharmacy pheno-groups and heart failure outcomes)","volume":"49","author":"Danjuma","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5339\/gcsp.2015.34","article-title":"Gulf CARE: heart failure in the Middle East","volume":"2015","author":"Hassan","year":"2015","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"B8","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/heartjnl-2022-321097","article-title":"Management of patients with heart failure and preserved ejection fraction","volume":"109","author":"Jasinska-Piadlo","year":"2023","journal-title":"Heart Br. Card. Soc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.japh.2017.06.002","article-title":"Association between Polypharmacy and death: a systematic review and meta-analysis","volume":"57","author":"Leelakanok","year":"","journal-title":"J. Am. Pharm. Assoc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/ejhf.3223","article-title":"Effects of sacubitril\/valsartan according to polypharmacy status in PARAGON-HF","volume":"26","author":"Matsumoto","year":"2024","journal-title":"Eur. J. Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/nejmoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1524-6175.2005.05298.x","article-title":"The ascot trial","volume":"7","author":"Moser","year":"","journal-title":"J. Clin. Hypertens."},{"key":"B14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/JCN.0000000000000885","article-title":"Polypharmacy and clinical outcomes in hospitalized patients with acute decompensated heart failure","volume":"38","author":"Ozasa","year":"2023","journal-title":"J. Cardiovasc Nurs."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/nejmoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2016.11.081","article-title":"Relationship between physical activity, body mass index, and risk of heart failure","volume":"69","author":"Pandey","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.22540\/jfsf-09-051","article-title":"What is the Association of Polypharmacy with frailty in heart failure? A systematic review and meta-analysis","volume":"9","author":"Prokopidis","year":"2024","journal-title":"J. Frailty, Sarcopenia Falls"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/circulationaha.120.045810","article-title":"Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction","volume":"142","author":"Sanders-van Wijk","year":"2020","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00392-022-02076-1","article-title":"Comorbidities complicating heart failure: changes over the last 15 years","volume":"112","author":"Screever","year":"2023","journal-title":"Clin. Res. Cardiol. Off. J. Ger. Card. Soc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes","volume":"126","author":"Steinberg","year":"2012","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/phar.2091","article-title":"Guideline-directed medical therapy and survival following hospitalization in patients with heart failure","volume":"38","author":"Tran","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e611","DOI":"10.1016\/S2214-109X(23)00605-8","article-title":"Mortality in patients admitted to hospital with heart failure in China: a nationwide Cardiovascular Association Database-Heart Failure Centre Registry cohort study","volume":"12","author":"Wang","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"28","year":"2022","journal-title":"J. Card. Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e027852","DOI":"10.1161\/jaha.122.027852","article-title":"Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the global burden of disease 2019 study","volume":"12","author":"Yan","year":"","journal-title":"J. Am. Heart Assoc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat. Rev. Cardiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1526112\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:15:46Z","timestamp":1746504946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1526112\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":30,"alternative-id":["10.3389\/fphar.2025.1526112"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1526112","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"article-number":"1526112"}}